18 Fluoro-2deoxy-d-glucose-positron emission tomography and locally advanced cervical cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 1, 2009, Pages 8-12

  Motton, Stéphanie ^a   De Lapparent, Thomas ^a   Brenot Rossi, Isabelle ^a   Buttarelli, Max ^a   Al Nakib, Maryam ^a   Jacquemier, Jocelyne ^a   Tallet, Agnés ^a   Houvenaeghel, Gilles ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Cervical cancer; Chemoradiation; FDG PET; Treatment response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ADVANCED CERVICAL CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SIZE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MINIMAL RESIDUAL DISEASE; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADICAL HYSTERECTOMY; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX CANCER; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; UTERINE CERVIX TUMOR;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; UTERINE CERVICAL NEOPLASMS;

EID: 65649095562     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGJ.0b013e318197f276     Document Type: Article

References (23)

1. Mohar A, Frias-Mendivil M. Epidemiology of cervical cancer. Cancer Invest. 2000;18(6):584-590.
2. Creasman WT. New gynecology cancer staging. Gynecol Oncol. 1995;58(2):157-158.
3. Green JA, Kirwan JM, Tierney J, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284): 781-786.
4. Dueñas-Gonzalez A, CetinaL, Mariscal I, et al. Modern management of locally advanced cervical carcinoma. Cancer Treat Rev. 2003;29(5): 389-399. Review.
5. Classe JM, Roche P, Rodier JF, et al. Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC. Gynecol Oncol. 2006;102(3):523-529.
6. Werburg O. On the origin cancer cell. Science. 1956;123:309-314.
7. Cave L. HCFA approves Medicare coverage of PET scans. J Natl Cancer Inst. 2001;93(3):177.
8. Digby W, Kepler J. The current status of PET. Radiol Manage. 2000; 22(1):37-40.
9. Rose PG, Adler LP, Rodriguez M, et al. PET for evaluation paraaortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol. 1999;17(1):41-45.
10. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy- dglucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21(19):3651-3658. Erratum in: J Clin Oncol. 2004; 22(1):209.
11. Bourguet P, Hitzel A, Houvenaeghel G, et al. SOR PET-FDG cancer du sein, de l'ovaire et de l'utérus 2006. Bull Cancer. 2006;93(4): 385-390.
12. Yen T, See LC, Lai CH, et al. FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45(1):22-29.
13. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology. 2001;218(3):776-782.
14. Follen M, Levenback CF, Lyer RB, et al. Imaging in cervical cancer. Cancer. 2003;98(9 Suppl):2028-2038. Review.
15. Narayan K, Hicks RJ, Jobling T, et al. A comparison of MRI and PET scanning in surgically staged locoregionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer. 2001; 11(4):263-271.
16. Chang TC, Law KS, Hong JH, et al. PET for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer. 2004; 101(1):164-171.
17. Park DH, Kim KH, Park JY, et al. Diagnosis of recurrent uterine cervical cancer: computed tomography versus PET. Korean J Radiol. 2000; 1(1):51-55.
18. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG-PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004;94(1):212-216.
19. Decker MA, Burke JJ, Gallup DG, et al. Completion hysterectomy after radiation therapy for bulky cervical cancer stages IB, IIA and IIB: complications and survival rates. Am J Obstet Gynecol. 2004;191(2): 654-658; discussion 658-660.
20. Resbeut M, Cowen D, Viens P, et al. Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. Gynecol Oncol. 1994;54(1):68-75.
21. Houvenaeghel G, Lelievre L, Rigouard AL, et al. Residual pelvic lymph node involvement after concomitant chemoradiation for locally advanced cervical cancer. Gynecol Oncol. 2005;102(1):74-79. Epub 2006 Jan 10.
22. Rouzier R, Morice P, De Crevoisier R, et al. Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. Eur J Surg Oncol. 2005;31(4):424-433.
23. Castellucci P, Zinzani P, Nanni C, et al. FDG-PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm. 2004;19(5):606-612.